DNA Capital is a global healthcare investment firm specializing in multi-stage investments, from early-stage venture capital to late-stage private equity. Founded in 2013 by Pedro Bueno, the firm is backed by the Bueno family, who established Amil, Brazil's largest healthcare company. With offices in São Paulo, Brazil, and San Francisco, California, DNA Capital partners with exceptional founders and management teams worldwide to build leading healthcare businesses.

The firm's investment approach spans various stages of company growth, including seed, early-stage, growth, and late-stage investments. DNA Capital's portfolio includes notable companies such as DASA, Mafra, and Cremer. The firm is committed to high-quality, ethical, and humane products and services, aiming to shape the future of healthcare through strategic investments.